Tissue Regenix Group PLC
LSE:TRX

Watchlist Manager
Tissue Regenix Group PLC Logo
Tissue Regenix Group PLC
LSE:TRX
Watchlist
Price: 0.0725 GBX Market Closed
Market Cap: £5.2m

Net Margin

-7.1%
Current
Improving
by 0.7%
vs 3-y average of -7.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-7.1%
=
Net Income
$-1.4m
/
Revenue
$26m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-7.1%
=
Net Income
GBX-1.4m
/
Revenue
$26m

Peer Comparison

Country Company Market Cap Net
Margin
UK
Tissue Regenix Group PLC
LSE:TRX
5.2m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 93% of companies in United Kingdom
Percentile
7th
Based on 3 670 companies
7th percentile
-7.1%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Tissue Regenix Group PLC
Glance View

Market Cap
5.2m GBX
Industry
Biotechnology

Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. The company is headquartered in Leeds, West Yorkshire and currently employs 79 full-time employees. The company went IPO on 2006-12-21. The firm is focused on the development of regenerative products using its two platform technologies: decellularization (dCELL), which is used to produce allograft (DermaPure) and xenograft (OrthoPure XT) soft tissue products to promote healing and regeneration, and BioRinse, which is a natural bone filler solution verified to be osteoinductive to stimulate and regenerate native bone growth. The firm is engaged in transforming the treatment of patients in surgical applications, including BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology and Cardiac.

TRX Intrinsic Value
0.621 GBX
Undervaluation 88%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-7.1%
=
Net Income
$-1.4m
/
Revenue
$26m
What is Tissue Regenix Group PLC's current Net Margin?

The current Net Margin for Tissue Regenix Group PLC is -7.1%, which is above its 3-year median of -7.8%.

How has Net Margin changed over time?

Over the last 3 years, Tissue Regenix Group PLC’s Net Margin has increased from -24.7% to -7.1%. During this period, it reached a low of -24.7% on May 30, 2022 and a high of -3.1% on Dec 31, 2024.

Back to Top